Published in

Wiley, Asia-Pacific Journal of Clinical Oncology, 2(18), 2021

DOI: 10.1111/ajco.13585

Links

Tools

Export citation

Search in Google Scholar

Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor

Journal article published in 2021 by On B. Chan, John C. Su ORCID, Anousha Yazdabadi, Arlene Chan ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractRibociclib is an inhibitor of cyclin‐dependent kinases 4 and 6 (CDK 4/6) that is used in combination with an aromatase inhibitor in the first‐line setting for advanced or metastatic hormone receptor positive and human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. We report two cases of drug‐induced vitiligo‐like depigmentation (DI‐VLD) associated with ribociclib. The awareness of this side effect is important given the increasing use of this drug and others with a similar mechanism of action.